MX2017015308A - Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer. - Google Patents

Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.

Info

Publication number
MX2017015308A
MX2017015308A MX2017015308A MX2017015308A MX2017015308A MX 2017015308 A MX2017015308 A MX 2017015308A MX 2017015308 A MX2017015308 A MX 2017015308A MX 2017015308 A MX2017015308 A MX 2017015308A MX 2017015308 A MX2017015308 A MX 2017015308A
Authority
MX
Mexico
Prior art keywords
cpg
antagonist
combination
treating cancer
type oligonucleotide
Prior art date
Application number
MX2017015308A
Other languages
English (en)
Inventor
Robert A Kastelein
L Coffman Robert
Guiducci Cristiana
Yu Ying
Evan Denker Andrew
Sadekova Svetlana
Truong Phan Uyen
Ross Kaufman David
S Janssen Robert
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2017015308A publication Critical patent/MX2017015308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente descripción describe terapias de combinación que comprenden un antagonista del Receptor de Muerte Programada 1 (PD-1) y un agonista del Receptor Tipo TolI 9 (TLR9) que es un oligonucleótido tipo CpG-C, y el uso de las terapias de combinación para el tratamiento de cáncer.
MX2017015308A 2015-05-29 2016-05-26 Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer. MX2017015308A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562168449P 2015-05-29 2015-05-29
US201562169309P 2015-06-01 2015-06-01
PCT/US2016/034275 WO2016196173A1 (en) 2015-05-29 2016-05-26 Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer

Publications (1)

Publication Number Publication Date
MX2017015308A true MX2017015308A (es) 2018-07-06

Family

ID=57441888

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017015308A MX2017015308A (es) 2015-05-29 2016-05-26 Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.

Country Status (13)

Country Link
US (2) US10751412B2 (es)
EP (2) EP3302501B1 (es)
JP (2) JP6893608B2 (es)
KR (1) KR20180014009A (es)
CN (1) CN108025018B (es)
AU (1) AU2016271018A1 (es)
BR (1) BR112017025562A2 (es)
CA (1) CA2986126A1 (es)
HK (1) HK1252652A1 (es)
MA (1) MA44699A (es)
MX (1) MX2017015308A (es)
RU (1) RU2017145558A (es)
WO (1) WO2016196173A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
CN115040532A (zh) 2014-10-10 2022-09-13 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
AU2015349680A1 (en) 2014-11-21 2017-06-08 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016109310A1 (en) * 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
EP3471753A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 and il-2 cytokines
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
MX2019002925A (es) 2016-09-15 2019-09-05 Idera Pharmaceuticals Inc Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
TW201900193A (zh) 2017-04-28 2019-01-01 美商默沙東藥廠 用於癌症治療之生物標記物
BR112019022873A8 (pt) 2017-05-02 2023-04-11 Merck Sharp & Dohme Formulação, e, vaso ou dispositivo de injeção.
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
JP2020536923A (ja) 2017-10-13 2020-12-17 メルク・シャープ・エンド・ドーム・コーポレイション びまん性大細胞型ｂ細胞リンパ腫を治療するための組成物及び方法
WO2019084418A1 (en) 2017-10-27 2019-05-02 Merck Sharp & Dohme Corp. COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER
JP7511478B2 (ja) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
TW202011959A (zh) * 2018-04-14 2020-04-01 美商戴納瓦克斯技術公司 用於治療癌症之包括CpG-C 型寡核苷酸及組蛋白去乙醯酶抑制劑之組合
WO2020081398A1 (en) * 2018-10-14 2020-04-23 Dynavax Technologies Corporation Combination including a cpg-c type oligonucleotide and a pd-1 antagonist for treating breast cancer
MX2021005394A (es) * 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
CN111303284A (zh) * 2018-12-12 2020-06-19 尚华科创投资管理（江苏）有限公司 抗人白细胞介素5(il-5)单克隆抗体及其应用
CN111321159B (zh) * 2018-12-14 2023-12-12 中天(上海)生物科技有限公司 用于免疫调节的嵌合核酸分子及其应用
US11613755B2 (en) 2019-12-31 2023-03-28 Industrial Technology Research Institute Nucleic acid-drug complex and use thereof
IL294621A (en) * 2020-01-10 2022-09-01 Sbi Biotech Co Ltd 9tlr agonistic oligonucleotides, preparations containing them and their uses
JP2023542989A (ja) * 2020-09-22 2023-10-12 トリサルース・ライフ・サイエンシズ・インコーポレイテッド トール様受容体アゴニストを使用したがん治療
EP4217064A4 (en) * 2020-09-22 2024-08-07 Trisalus Life Sciences Inc CANCER THERAPY WITH TOLL-LIKE RECEPTOR AGONISTS
WO2022110010A1 (zh) * 2020-11-27 2022-06-02 苏州吉玛基因股份有限公司 免疫激活剂、抗原和抗体在制备预防、治疗肿瘤产品中的应用
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
WO2023081486A1 (en) 2021-11-08 2023-05-11 Nurix Therapeutics, Inc. Toll-like receptor therapy combinations with cbl-b inhibitor compounds
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6217857B1 (en) 1989-06-28 2001-04-17 Schering Corporation Cytokine synthesis inhibitory factor (IL-10) and pharmaceutical compositions thereof
DE69739515D1 (de) 1996-01-30 2009-09-10 Univ California Expressionsvektoren, die eine antigen-spezifische immunantwort induzieren, und methoden für ihre verwendung.
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
PT1003850E (pt) 1997-06-06 2009-08-13 Dynavax Tech Corp Inibidores da actividade de sequências de adn imunoestimulantes
DK1009413T3 (da) 1997-09-05 2007-06-11 Univ California Anvendelse af immunstimulerende oligonukleotider til forebyggelse eller behandling af astma
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
CA2430691A1 (en) 2000-12-27 2002-07-04 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
DK1575977T3 (da) * 2002-12-23 2009-11-09 Dynavax Tech Corp Oligonukleotider med Immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
ATE514713T1 (de) 2002-12-23 2011-07-15 Wyeth Llc Antikörper gegen pd-1 und ihre verwendung
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
AR046833A1 (es) 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
BRPI0713000A8 (pt) * 2006-06-12 2017-12-05 Trubion Pharmaceuticals Inc Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
EP2170959B1 (en) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
CN102203125A (zh) 2008-08-25 2011-09-28 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
CA2998281C (en) 2008-09-26 2022-08-16 Dana-Farber Cancer Institute, Inc. Human anti-pd-1 antobodies and uses therefor
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제
CN108997498A (zh) 2008-12-09 2018-12-14 霍夫曼-拉罗奇有限公司 抗-pd-l1抗体及它们用于增强t细胞功能的用途
PL3903829T3 (pl) * 2009-02-13 2023-08-14 Immunomedics, Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
WO2012006634A2 (en) * 2010-07-09 2012-01-12 The Board Of Trustees Of The University Of Illiniois Prostate specific antigen (psa) peptide therapy
MX341076B (es) * 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
PE20190262A1 (es) 2011-08-01 2019-02-25 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
AR091220A1 (es) * 2012-05-31 2015-01-21 Genentech Inc Metodos para tratar cancer usando antagonistas de union a pd-1 axis y antagonistas de vegf
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
US20160084839A1 (en) 2013-04-02 2016-03-24 Marisa Dolled-Filhart Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
BR112016007891A2 (pt) * 2013-10-11 2017-12-05 Constellation Pharmaceuticals Inc uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
US10278984B2 (en) 2014-05-02 2019-05-07 Nitor Therapeutics Guanosine as an immune potentiator mediated through toll receptors
CN115040532A (zh) 2014-10-10 2022-09-13 伊黛拉制药有限公司 使用tlr9激动剂与检查点抑制剂对癌症的治疗
WO2016109310A1 (en) * 2014-12-31 2016-07-07 Checkmate Pharmaceuticals, Llc Combination tumor immunotherapy
CN107949399A (zh) 2015-05-29 2018-04-20 默沙东公司 用于治疗癌症的抗‑IL‑10抗体和CpG‑C型寡核苷酸的组合产品
WO2016196173A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer

Also Published As

Publication number Publication date
MA44699A (fr) 2021-05-05
CN108025018B (zh) 2021-08-17
JP6893608B2 (ja) 2021-06-23
JP2021102627A (ja) 2021-07-15
JP2018516911A (ja) 2018-06-28
EP3892284B1 (en) 2024-05-22
AU2016271018A1 (en) 2017-11-30
CN108025018A (zh) 2018-05-11
US10751412B2 (en) 2020-08-25
US20180169229A1 (en) 2018-06-21
BR112017025562A2 (pt) 2018-08-07
EP3302501B1 (en) 2021-09-22
EP3302501A1 (en) 2018-04-11
CA2986126A1 (en) 2016-12-08
HK1252652A1 (zh) 2019-05-31
EP3892284A1 (en) 2021-10-13
WO2016196173A1 (en) 2016-12-08
US11918648B2 (en) 2024-03-05
EP3302501A4 (en) 2019-02-27
US20210196819A1 (en) 2021-07-01
JP7236483B2 (ja) 2023-03-09
RU2017145558A (ru) 2019-07-01
KR20180014009A (ko) 2018-02-07

Similar Documents

Publication Publication Date Title
MX2017015308A (es) Combinacion de un antagonista de pd-1 y un oligonucleotido tipo cpg-c para tratar cancer.
PH12017501857A1 (en) Pd-l1 antagonist combination treatments
MX2016010082A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1) y un inhibidor del receptor del factor de crecimiento endotelial vascular (vegfr) para tratar cancer.
PH12016501550A1 (en) Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
TW201613635A (en) Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
MA40344A (fr) Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
MX2016002273A (es) Tratamiento de cancer con una combinacion de un antagonista de proteina de muerte programada 1 y dinaciclib.
IL270720A (en) Combination of treatments for cancer treatment
MX2017011206A (es) Combinacion de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cancer.
MX2017006320A (es) Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2016015363A (es) Terapias de combinacion para el tratamiento de cancer.
EA201791133A1 (ru) Ингибиторы erk
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
MX2016007885A (es) Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
MX2020003770A (es) Terapias de combinacion para tratar cancer.
IL270511A (en) Combined treatments using niraparib and pembrolizumab for the treatment of cancer
MX2023006706A (es) Administracion transdermica de agentes grandes en composiciones de emulsion mediante acondicionamiento de la piel con microagujas y sus usos.
MX2019003994A (es) Combinacion de un antagonista de proteina de muerte programada-1 (pd-1) y eribulina para el tratamiento de cancer urotelial.
MX2024000253A (es) Inhibicion del smarca2 para el tratamiento del cancer.
MA40364A (fr) Polythérapie pour le traitement du cancer
MA40457A (fr) Combinaison de médicaments pour traiter le myélome multiple
MX2017015311A (es) Combinacion de un anticuerpo anti-il-10 y un oligonucleotido tipo cpg-c para tratar cancer.
NZ743720A (en) Cftr regulators and methods of use thereof
MX2021006326A (es) Inhibidores de pcna.